- ►diabetesjournals.org N Hotta, Y Akanuma, R Kawamori, K Matsuoka, … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor
nerve conduction velocity (MNCV) ≥40 m/s, and HbA 1c ≤9% were enrolled in
this open-label, multicenter study and randomized to 150 mg/day epalrestat ... Cited by 46 - Related articles - BL Direct - All 5 versions
H Kamiya, J Nakamura, Y Hamada, E … - Diabetes/Metabolism Reviews - interscience.wiley.com Polyol pathway hyperactivity-induced decreases in protein kinase C (PKC)
activities have been proposed as a pathogenic mechanism of diabetic neuropathy.
Increased PKC activities have recently been invoked in the pathogenesis of ... Cited by 21 - Related articles - BL Direct - All 3 versions
KC Donaghue, SH Margan, AK Chan, B … - Diabetic Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 12 - Related articles - BL Direct - All 4 versions
YIN Xiao-xing, Y ZHANG, S Jian-ping, WU Hai … - Acta Pharmacologica Sinica, 2005 - chinaphar.com Aim: To investigate the preventive and protective effects of bendazac lysine
(BDL) on experimental early diabetic nephropathy (DN) rats. Methods: After an
early DN model was induced by streptozotocin, rats were administered BDL at ... Cited by 11 - Related articles - Cached - BL Direct - All 7 versions
- ►diabetesjournals.org K Thamotharampillai, AKF Chan, B Bennetts, … - Diabetes care, 2006 - Am Diabetes Assoc RESULTS—Median time between first and last assessment was 7.0 years
(interquartile range 5.1–11.1), with a median of five assessments (four to
seven) per individual. At first assessment, median age was 12.7 years ... Cited by 9 - Related articles - BL Direct - All 5 versions
N Zaher, I Nicolaou, VJ Demopoulos - Journal of Enzyme Inhibition and Medicinal Chemistry, 2002 - informahealthcare.com Activation of the aldose reductase enzyme (AR, ALR2, EC 1.1.1.21) of the polyol
pathway has suggested that it is implicated in a number of pathological
conditions: a) in diabetic patients, for the development of the long term ... Cited by 7 - Related articles - BL Direct - All 7 versions
BC Cumbie, KL Hermayer - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov Microvascular complications characterized by retinopathy, nephropathy, and
neuropathy are highly prevalent among diabetics. Glycemic control has long been
the mainstay for preventing progression of these complications; however, ... Cited by 5 - Related articles - BL Direct - All 8 versions
N Hotta, R Kawamori, Y Atsumi, M Baba, H … - Diabetic Medicine, 2008 - pubmedcentral.nih.gov Stratified analyses were conducted on data from patients in the Aldose Reductase
Inhibitor—Diabetes Complications Trial (ADCT). The ADCT included patients with
diabetic peripheral neuropathy, median motor nerve conduction velocity ≥ ... Cited by 4 - Related articles - All 5 versions
